These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22793527)

  • 21. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma.
    Takaku Y; Soma T; Nishihara F; Nakagome K; Kobayashi T; Hagiwara K; Kanazawa M; Nagata M
    Int Arch Allergy Immunol; 2013; 161 Suppl 2():107-17. PubMed ID: 23711861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.
    Molimard M; Mala L; Bourdeix I; Le Gros V
    Respir Med; 2014 Apr; 108(4):571-6. PubMed ID: 24565601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry.
    de Llano LP; Vennera Mdel C; Álvarez FJ; Medina JF; Borderías L; Pellicer C; González H; Gullón JA; Martínez-Moragón E; Sabadell C; Zamarro S; Picado C;
    J Asthma; 2013 Apr; 50(3):296-301. PubMed ID: 23350994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profile of patients treated with omalizumab in routine clinical practice in Spain.
    Ancochea J; Chivato T; Casan P; Picado C; Herráez L; Casafont J
    Allergol Immunopathol (Madr); 2014; 42(2):102-8. PubMed ID: 23267505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG; Higgins B; Chilvers ER; Ayre G; Blogg M; Fox H
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands.
    van Nooten F; Stern S; Braunstahl GJ; Thompson C; Groot M; Brown RE
    J Med Econ; 2013; 16(3):342-8. PubMed ID: 23216016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral centre for asthma in Ireland.
    Subramaniam A; Al-Alawi M; Hamad S; O'Callaghan J; Lane SJ
    QJM; 2013 Jul; 106(7):631-4. PubMed ID: 23550166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
    Long A; Rahmaoui A; Rothman KJ; Guinan E; Eisner M; Bradley MS; Iribarren C; Chen H; Carrigan G; Rosén K; Szefler SJ
    J Allergy Clin Immunol; 2014 Sep; 134(3):560-567.e4. PubMed ID: 24679845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Omalizumab in the treatment of asthma.
    Tan R; Corren J
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical experience with omalizumab in a Portuguese severe asthma unit.
    Alfarroba S; Videira W; Galvão-Lucas C; Carvalho F; Bárbara C
    Rev Port Pneumol; 2014; 20(2):78-83. PubMed ID: 24525397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Omalizumab: new drug. Asthma: too many unknowns for an anti-IgE.
    Prescrire Int; 2007 Oct; 16(91):179-82. PubMed ID: 17926440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes before and after treatment escalation to Global Initiative for Asthma steps 4 and 5 in severe asthma.
    Sullivan PW; Campbell JD; Ghushchyan VH; Globe G
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):462-9. PubMed ID: 25890451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y; Dobashi K; Fueki N; Fueki M; Okada T; Tomioka S; Makino S; Mori M
    J Biol Regul Homeost Agents; 2011; 25(2):177-86. PubMed ID: 21880206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.
    Yalcin AD; Gorczynski RM; Parlak GE; Kargi A; Bisgin A; Sahin E; Kose S; Gumuslu S
    Clin Lab; 2012; 58(1-2):89-96. PubMed ID: 22372350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
    Rottem M
    J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.